Research output

Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

Associated organisations

    Research areas

  • Metastatic breast cancer, Bevacizumab, Cost-effectiveness analysis, Real-world, Trial based, Cost-benefit analysis, RANDOMIZED PHASE-III, 1ST-LINE TREATMENT, PLUS DOCETAXEL, PACLITAXEL, WOMEN
View graph of relations


Original languageEnglish
Pages (from-to)238-246
Number of pages9
JournalEuropean Journal of Cancer
Publication statusPublished - Jul 2017